These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30419769)

  • 1. A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy.
    Kim S
    J Oncol Pharm Pract; 2019 Oct; 25(7):1787-1793. PubMed ID: 30419769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature.
    Maalouf NM; Heller HJ; Odvina CV; Kim PJ; Sakhaee K
    Endocr Pract; 2006; 12(1):48-53. PubMed ID: 16524863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamidronate-induced irreversible symptomatic hypocalcemia in a dog with hypercalcemia after glucocorticoid withdrawal: a case report.
    Oh YI; An JH; Lim GH; Park SM; Kim TH; Seo KW; Youn HY
    BMC Vet Res; 2024 May; 20(1):227. PubMed ID: 38790012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Management of Severe Hypercalcemia with Zoledronic Acid: A Report of Two Pediatric Cases.
    Kilci F; Jones JH; Çizmecioğlu-Jones FM
    J Clin Res Pediatr Endocrinol; 2024 May; 16(2):224-228. PubMed ID: 36264042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports.
    Champallou C; Basuyau JP; Veyret C; Chinet P; Debled M; Chevrier A; Grongnet MH; Brunelle P
    J Pain Symptom Manage; 2003 Feb; 25(2):185-90. PubMed ID: 12590034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report.
    Mahmoud S; Mitwally H; El Zeer HS; El Madhoun I; Khatib M
    Am J Case Rep; 2018 Sep; 19():1087-1089. PubMed ID: 30209247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
    Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
    Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
    Major P
    Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
    Major PP; Coleman RE
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ
    Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe infantile hypercalcemia associated with Williams syndrome successfully treated with intravenously administered pamidronate.
    Cagle AP; Waguespack SG; Buckingham BA; Shankar RR; Dimeglio LA
    Pediatrics; 2004 Oct; 114(4):1091-5. PubMed ID: 15466114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
    Sims EC; Rogers PB; Besser GM; Plowman PN
    Clin Oncol (R Coll Radiol); 1998; 10(6):407-9. PubMed ID: 9890546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypercalcemia and childhood cancer: a 7-year experience.
    Kerdudo C; Aerts I; Fattet S; Chevret L; Pacquement H; Doz F; Michon J; Garabedian M; Orbach D
    J Pediatr Hematol Oncol; 2005 Jan; 27(1):23-7. PubMed ID: 15654274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.